Loading...
 
Back to the list
Mediterr J Rheumatol 2018;29(2):92-6
Article Links
Sjögren Syndrome Associated with Inflammatory Muscle Diseases
Michail P. Migkos1, Ioannis Sarmas2, George Α. Somarakis1, Paraskevi V. Voulgari1, Konstantinos I. Tsamis2, Alexandros A. Drosos1
Authors Information

1: Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina Greece
2: Neurosurgical Institute, University of Ioannina School of Medicine, Ioannina, Greece; Department of Neurology, University Hospital of Ioannina, Ioannina, Greece

Keywords: Sjögren Syndrome, Inflammatory Myopathies, Inclusion Body Myositis, Polymyositis, Dermatomyositis
References
  1. Moutsopoulos H M. Sjögren’s syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994;72:162-5.
  2. Moutsopoulos H M. Sjögren’s syndrome or autoimmune epithelitis? Clinic Rev Allerg Immunol 2007;32:199-200. 
  3. Andonopoulos A P, Lagos G, Drosos A A, Moutsopoulos H M. The spectrum of neurological involvement in Sjögren's syndrome. Br J Rheumatol 1990;29:21-3.
  4. Papathanasiou M P, Constantopoulos S H, Tsampoulas C, Drosos A A, Moutsopoulos H M. Reappraisal of respiratory abnormalities in primary and secondary Sjögren's syndrome. A controlled study. Chest 1986;90:370-4. 
  5. Tsianos E B, Chiras C D, Drosos A A, Moutsopoulos H M. Oesophageal dysfunction in patients with primary Sjögren's syndrome. Ann Rheum Dis 1985;44:610-3.
  6. Ramos-Casals N, Tzioufas A G, Font J. Primary Sjögren’s syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005;64:347-54. 
  7. Moutsopoulos H M, Webber B L, Vlagopoulos T P, Chused T M, Decker J L. Differences in the clinical manifestations of sicca syndrome in the presence and absence of rheumatoid arthritis.  Am J Med 1979;66:733-6.
  8. Baer A N, Maynard J W, Shaikh F, Magder L S, Petri M. Secondary Sjögren's syndrome in systemic lupus erythematosus defines a distinct disease subset. J Rheumatol 2010;37:1143-9.
  9. Andonopoulos A P, Drosos A A, Skopouli F N, Acritidis N C, Moutsopoulos H M. Secondary Sjögren's syndrome in rheumatoid arthritis. J Rheumatol 1987;14:1098-103.
  10. Drosos A A, Andonopoulos A P, Costopoulos J S, Stavropoulos E D, Papadimitriou C S, Moutsopoulos H M. Sjögren's syndrome in progressive systemic sclerosis. J Rheumatol 1988;15:965-8.
  11. Bohan A, Peter J B. Polymyositis and dermatomyositis. N Engl J Med 292:344-7. https://doi.org/10.1056/NEJM197502132920706
  12. Dalakas M C. Inflammatory muscle diseases. N Engl J Med 2015;372:1734-47.
  13. Kraus A, Cifuentes M, Villa A R, Jakez J, Reyes E, Alarcón-Segovia D. Myositis in primary Sjögren syndrome. Report of 3 cases. J Rheumatol 1994;21:649-53.
  14. Alexander E L, Josifek L Provost T T, Alexander G E. Myositis/vasculitis in primary Sjögren’s syndrome (abstr) Arthritis Rheum 1982;25:S15.
  15. Leroy J P, Drosos A A, Yiannopoulos P, Moutsopoulos H M. Intravenous pulse cyclophosphamide therapy in myositis and Sjögren’s syndrome. Arthritis Rheum 1990;33:1579-81. 
  16. Alexander E L. Neuromuscular complications of primary Sjögren’s syndrome. In: Talal N, Moutsopoulos H M, Kassan S S, editors.  Sjögren’s syndrome. Clinical and immunological aspects. Berlin: Springer; 1987;61-82. 
  17. Colafrancesco S, Priori R, Gattamelata A, et al. Myositis in primary Sjögren’s syndrome: data from a multicentre cohort. Clin Exp Rheumatol 2015;33:457-64.
  18. Kanellopoulos P, Baltoyiannis C, Tzioufas A G. Primary Sjögren's syndrome associated with inclusion body myositis. Rheumatology (Oxford) 2002;41:440-4. 
  19. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8. 
  20. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011;134:3176-84. 
  21. Dalakas M C, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology 1997;48:712-6.
  22. Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002;58:326.
  23. Misterska-Skóra M, Sebastian A, Dzięgiel P, Sebastian M, Wiland P. Inclusion body myositis associated with Sjögren's syndrome. Rheumatol Int 2013;33:3083-6. 
  24. Aoki A, Ono S, Ueda A, et al. Myositis in primary Sjögren's syndrome: clinical and pathological report. Mod Rheumatol 2003;13:57-61.
  25. Imasaki T, Yoshii A, Tanaka S, Ogura T, Ishikawa A, Takahashi T. Polymyositis and Sjögren's syndrome associated with bronchiolitis obliterans organizing pneumonia. Intern Med 1996;35:231-5. 
  26. Ringel S P, Forstot J Z, Tan E M, Wehling C, Griggs R C, Butcher D. Sjögren's syndrome and polymyositis or dermatomyositis. Arch Neurol 1982;39:157-63. 
  27. Ferro F, Vagelli R, Bruni C, et al. One year in review 2016: Sjögren's syndrome. Clin Exp Rheumatol 2016;34:161-71.
  28. Ioannidis J P, Vassiliou V A, Moutsopoulos HM. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome. Arthritis Rheum 2002;46:741-7.
  29. Hamann P D, Cooper R G, McHugh N J, Chinoy H. Statin-induced necrotizing myositis - a discrete autoimmune entity within the "statin-induced myopathy spectrum". Autoimmun Rev 2013;12:1177-81. https://doi.org/10.1016/j.autrev.2013.07.001 
  30. Dalakas M C. Necrotising autoimmune myopathy (NAM): antibodies seem to be specific markers in aiding diagnosis. J Neurol Neurosurg Psychiatry 2016;87:1037. https://doi.org/10.1136/jnnp-2016-313418
  31. Stein M, Bell M J, Ang L C. Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000;27:2927-31.
  32. Rigolet A, Musset L, Dubourg O, Maisonobe T, Grenier P, Charuel J L, et al. Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease. Medicine (Baltimore) 2012;91:95-102. 
  33. Wielosz E, Majdan M, Jeleniewicz R, Mazurek M. Autoimmune diseases with the presence of anti-ku antibodies - analysis of three cases. Wiad Lek 2016;69:24-6.
  34. Fiorentino D F, Presby M, Baer A N, Petri M, Rieger K E, Soloski M,  et al. PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome. Ann Rheum Dis 2016;75:1145-51.